Marshall Wace LLP Sells 195,019 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Marshall Wace LLP trimmed its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 16.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 993,593 shares of the biopharmaceutical company's stock after selling 195,019 shares during the period. Marshall Wace LLP owned 0.60% of ACADIA Pharmaceuticals worth $18,232,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in ACAD. Vanguard Group Inc. lifted its holdings in shares of ACADIA Pharmaceuticals by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 13,947,640 shares of the biopharmaceutical company's stock worth $255,939,000 after acquiring an additional 104,444 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of ACADIA Pharmaceuticals by 1.1% during the third quarter. Geode Capital Management LLC now owns 2,875,540 shares of the biopharmaceutical company's stock valued at $44,234,000 after acquiring an additional 30,826 shares in the last quarter. SG Americas Securities LLC lifted its stake in shares of ACADIA Pharmaceuticals by 380.3% during the fourth quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company's stock worth $45,576,000 after buying an additional 1,966,607 shares during the period. Norges Bank purchased a new stake in ACADIA Pharmaceuticals during the 4th quarter valued at about $25,555,000. Finally, Renaissance Technologies LLC boosted its holdings in ACADIA Pharmaceuticals by 204.2% in the fourth quarter. Renaissance Technologies LLC now owns 1,226,533 shares of the biopharmaceutical company's stock valued at $22,507,000 after purchasing an additional 823,333 shares during the last quarter. 96.71% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at ACADIA Pharmaceuticals

In related news, EVP Mark C. Schneyer sold 2,708 shares of ACADIA Pharmaceuticals stock in a transaction on Tuesday, April 8th. The stock was sold at an average price of $14.82, for a total transaction of $40,132.56. Following the completion of the sale, the executive vice president now owns 59,456 shares of the company's stock, valued at approximately $881,137.92. This trade represents a 4.36 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Elizabeth A. Garofalo sold 4,919 shares of the business's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $18.23, for a total value of $89,673.37. Following the completion of the sale, the director now directly owns 17,595 shares of the company's stock, valued at approximately $320,756.85. This trade represents a 21.85 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 14,169 shares of company stock worth $242,686 over the last three months. Company insiders own 28.30% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on ACAD shares. StockNews.com raised shares of ACADIA Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday, March 8th. Guggenheim lowered ACADIA Pharmaceuticals from a "buy" rating to a "neutral" rating and reduced their price target for the company from $23.00 to $20.00 in a research report on Friday, January 3rd. Morgan Stanley restated an "equal weight" rating and set a $20.00 target price on shares of ACADIA Pharmaceuticals in a research note on Friday, March 7th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of ACADIA Pharmaceuticals in a report on Tuesday, February 11th. They issued a "hold" rating and a $22.00 target price for the company. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $28.00 price target on shares of ACADIA Pharmaceuticals in a report on Thursday, February 27th. Eight research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, ACADIA Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $23.93.

ACADIA Pharmaceuticals Trading Down 1.2 %

ACAD stock traded down $0.18 during mid-day trading on Friday, hitting $14.66. The stock had a trading volume of 284,005 shares, compared to its average volume of 1,845,127. The firm has a fifty day simple moving average of $16.74 and a 200 day simple moving average of $16.92. The firm has a market capitalization of $2.44 billion, a P/E ratio of 18.81 and a beta of 0.54. ACADIA Pharmaceuticals Inc. has a 52 week low of $13.40 and a 52 week high of $20.68.

ACADIA Pharmaceuticals Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.